News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medtronic, Inc. (MDT) Announces Appeal Decision in Patent Litigation with DePuy Spine, Inc.


6/2/2009 7:39:31 AM

Bookmark and Share

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT - News), today announced results from a Federal Circuit Court review of a December 2007 patent infringement verdict regarding the Vertex line of multiaxial screws, which are no longer on the market. The Appeals Court upheld the verdict of patent infringement, but reversed a substantial portion of the damages award to DePuy Spine. The Appeals Court also reversed a sanctions determination against Medtronic, finding that it was legally incorrect and could not be sustained. The Appeals Court affirmed an award of $149.1 million in lost profits, but eliminated another $77.2 million in damages to DePuy Spine, along with another approximate $10.5 million in sanctions and attorneys’ fees.

“We are pleased that the judgment will be reduced by a very substantial amount as a result of this appeal, and that the right to a vigorous trial defense was upheld,” said Steve La Neve, president of the Spinal and Biologics business and senior vice president at Medtronic. “It is important to note that this case has no bearing on our current Vertex Select and OC Systems.”

The case will now be remanded to the trial court for calculation of the reduced judgment, which will include amounts both for post-judgment and prejudgment interest on the damages.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the world’s leading medical technology company, alleviating pain, restoring health, and extending life for people with chronic disease.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 25, 2008. Actual results may differ materially from anticipated results.

Contact:

Medtronic, Inc. Marybeth Thorsgaard, 763-505-2644 Public Relations Jeff Warren, 763-505-2696 Investor Relations


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES